CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2026 Financial Results
CRISPR Therapeutics reported Q2 2026 total revenue of $10.2 million, driven by CASGEVY product revenue of $76 million, which grew 151% year-over-year. The FDA approved CASGEVY for children as young as 2 years old with SCD or TDT, significantly expanding the addressable patient population by approximately 5,500 individuals. Pipeline execution continued with the initiation of Phase 1 trials for CTX340 in refractory hypertension and CTX460 in alpha-1 antitrypsin deficiency. The company also provided updates on its CTX310, CTX611, and zugo-cel programs across cardiovascular and autoimmune indications.
Key figures
- Revenue
- 10181000
- Net loss
- $91.2 million
- Cash position
- $2,364.4 million
- Casgevy revenue
- $76 million
- Casgevy qoq growth
- 78%
- Casgevy yoy growth
- 151%
- Convertible note proceeds
- $585.4 million
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.